Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Since the beginning of COVID-19 pandemic situation, several modes of ventilation have been tried to correct the hypoxaemia induced by SARS-CoV-2 virus. A few recent studies have concluded that high-flow nasal oxygen therapy (OptiFlowâ„¢) is beneficial in COVID-19. All mainly conclude that the use of OptiFlowâ„¢ avoid intubations and decrease hospitalization duration in critical care services.
At the emergency medical service 83 (SAMU 83), it has been decided to extend this ventilation mode during patient secondary transfers (transfer from an intensive care unit/other hospital unit/emergency department to another hospital's intensive care unit).
The emergency medical service 83 has equipped its intensive-care ambulances with OptiFlowâ„¢ in order not to interrupt this ventilation mode during transport.
The hypothesis is that patients with a severe respiratory form of COVID-19 transported from one health facility to another by the emergency medical service 83 on high-flow nasal oxygen therapy has a reduced risk of intubation compared to the other modes of non-invasive ventilation (NIV) and High Concentration oxygen Masks (HCM).
Retrospective observational study in France including COVID-19 infected patients taken care of by the emergency medical service 83 (SAMU 83) for a secondary transport between1st March 2020 and 31th December 2021.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients treated by high flow nasal oxygen therapy (Optiflowâ„¢) |
| ||
| Patients treated by other non-invasive ventilation or high concentration oxygen masks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Use of high flow nasal oxygen therapy | Device | Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Intubation rate | Rate of intubation during the first 24 hours after arrival in the destination Intensive Care Unit (ICU) | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality rate | Rate of patients alive at Day 28. | 28 days |
| ICU length of stay | Number of days spent in intensive care unit of destination |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients more than 18 year old taken care of by the emergency medical service 83 (SAMU 83) for secondary transport (transfer from an intensive care unit/other hospital unit/emergency department to another hospital's intensive care unit) between1st March 2020 and 31th December 2021 and without pre-transport intubation
Not provided
| Name | Affiliation | Role |
|---|---|---|
| BOUTIN Célia, MD | Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hopitalier Intercommunal Toulon - La Seyne sur Mer | Toulon | Var | 83056 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Use of other non-invasive ventilation or high concentration oxygen masks | Device | Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83). |
|
| At the moment of Intensive care unit discharge, up to 1 month |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided